Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.

Morand EF, Dall'Era M, Sanchez-Guerrero J, Pearson DR, Werth VP, Wenzel J, Roy S, Kleinmond C, Gühring H, Sgouroudi E, Klopp-Schulze L, Moreau F, Fernandez-Ruiz R, Furie R

Open source

DOI
10.1016/s0140-6736(26)00463-0
Published
2026 May 9
Container
Lancet (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00463-0,
  title = {Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.},
  author = {Morand EF and Dall'Era M and Sanchez-Guerrero J and Pearson DR and Werth VP and Wenzel J and Roy S and Kleinmond C and Gühring H and Sgouroudi E and Klopp-Schulze L and Moreau F and Fernandez-Ruiz R and Furie R},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00463-0},
  url = {https://doi.org/10.1016/s0140-6736(26)00463-0}
}

RIS

TY  - JOUR
TI  - Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.
AU  - Morand EF
AU  - Dall'Era M
AU  - Sanchez-Guerrero J
AU  - Pearson DR
AU  - Werth VP
AU  - Wenzel J
AU  - Roy S
AU  - Kleinmond C
AU  - Gühring H
AU  - Sgouroudi E
AU  - Klopp-Schulze L
AU  - Moreau F
AU  - Fernandez-Ruiz R
AU  - Furie R
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00463-0
UR  - https://doi.org/10.1016/s0140-6736(26)00463-0
ER  - 

APA

EF, M., M, D., J, S., DR, P., VP, W., J, W., S, R., C, K., H, G., E, S., L, K., F, M., R, F., & R, F. (2026). Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00463-0

Source records